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Abstract
Myotonic dystrophy type 1 (DM1) is a rare genetic disorder, characterised by muscular dys-
trophy, myotonia, and other symptoms. DM1 is caused by the expansion of a CTG repeat in
the 3’-untranslated region of DMPK. Longer CTG expansions are associated with greater
symptom severity and earlier age at onset. The primary mechanism of pathogenesis is
thought to be mediated by a gain of function of the CUG-containing RNA, that leads to trans-
dysregulation of RNA metabolism of many other genes. Specifically, the alternative splicing
(AS) and alternative polyadenylation (APA) of many genes is known to be disrupted. In the
context of clinical trials of emerging DM1 treatments, it is important to be able to objectively
quantify treatment efficacy at the level of molecular biomarkers. We show how previously
described candidate mRNA biomarkers can be used to model an effective reduction in CTG
length, using modern high-dimensional statistics (machine learning), and a blood and mus-
cle mRNA microarray dataset. We show how this model could be used to detect treatment
effects in the context of a clinical trial.
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Introduction
Myotonic dystrophy type 1
Myotonic dystrophy type 1 (DM1) is an autosomal dominant trinucleotide repeat disorder,
caused by an expanded CTG repeat in the 3’ UTR of the dystrophia myotonica protein kinase
(DMPK) gene [1]. Transcription of DMPK in affected individuals produces a toxic, GC-rich
mRNA molecule, which results in dysregulation of several RNA binding factors, including pro-
teins MBNL1, MBNL2, MBNL3, CELF1 (CUGBP1), HNRNPH1 and STAU1 (Staufen1) [2, 3].
The pathomechanism of the dysregulation of splicing factor MBNL1 is perhaps best under-
stood, with MBNL1 sequestration to the toxic DMPK RNA product resulting in alternative
splicing defects of pre-mRNAs of multiple genes, including the chloride channel (CLCN1),
brain microtubule-associated tau (MAPT) and insulin receptor (INSR) [4]. Such alternative
splicing (AS) defects are generally believed to be a major contributing factor of clinical symp-
toms of DM1, such as myotonia (CLCN1) or abnormal glucose response (INSR), and have been
postulated to play a role in cardiac conduction defects (RYR2, SERCA2, TNNT2) [5]. AS defects
may underlie other clinical symptoms of DM1, including muscle wasting, cataracts, hypersom-
nia, gastrointestinal abnormalities, as well as premature baldness and testicular atrophy in
males [2, 6]. The severity of symptoms is positively correlated with CTG repeat length [2].
The toxic DMPK transcript in DM1-affected individuals has been identified as an active tar-
get for theraupetic intervention [7], and it is expected that breakdown of the toxic mRNA will
result in at least partial reversal of DM1-induced AS changes and other known and unknown
DM1-induced biomolecular pathologies.
Spliceopathy of DM1 is an active area of research, with novel splicing defects being continu-
ously reported. Nakamori et al. [8] identified a set of 41 genes, which are mis-spliced in DM1,
suggesting these genes as potential biomarkers of DM1. Batra et al. [9] identified 80 genes,
whose expression indicates disrupted APA, reusing the (human) dataset of Nakamori et al.
and using other datasets, including data from mouse models.
Predictors in genetics research
A widespread paradigm in biological and clinical research is the case-control study, using fre-
quentist statistics tools focusing on hypothesis testing (inference). Examples of such designs
include Genome Wide Association Studies (GWAS) [10], placebo and active control clinical
trial designs [11], non-inferiority designs [12] or heredity designs based on twin studies. It is
reported that designs of as many as 70% of studies published in leading medical journals use at
most the following three statistical tests as part of their design: Student’s t-test, Fisher’s exact
test, and the Chi-square test [13].
A possible alternative to the focus on hypothesis testing is building predictors or classifiers,
which produce a numerical estimate of a given trait (height, size of the DM1 trinucleotide
expansion) or effect size, predict participant’s category (such as affected/unaffected), or esti-
mate the effect size of the treatment, given a set of independent variables (e.g. genotypes,
mRNA profiles, etc.). If necessary, the efficacy of these predictors/classifiers can be evaluated
using traditional frequentist tools, such as p-values.
Predictors have been successfully applied in genetics research. For example, Lello et al. [14]
report predicting human height from genotype data, obtained using human Single Nucleotide
Polymorphism (SNP) microarrays, to within a few centimeters for most participants in their
sample. This level of accuracy is achieved due to a very large sample size of nearly half a million
individuals. A review by Van Raden et al. [15] reports ability to predict dairy output of certain
cattle breeds with R2 of 49%, using non-linear models based on SNP microarrays. The work of
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Azencott et al. [16] allows one to incorporate prior information about biological networks into
the predictive model, increasing prediction accuracy. In one of the direct motivations behind
our research here, Lee et al. [17] report being able to predict most of Huntington disease trinu-
cleotide repeat size using mRNA profiling of lymphoblastoid cell lines. Here, we demonstrate
a further application of predictors in genetics research, by constructing a predictor, which can
produce a numerical estimate of a participant’s DM1 CTG repeat length (measured from
blood) from an mRNA profile (obtained from muscle), and demonstrate its usefulness in the
context of a hypothetical clinical trial of a DM1 treatment.
Prior identification of alternative splicing and alternative polyadenylation
events in muscles of DM1-affected individuals
Our primary reference is the work of Nakamori et al. [8], who identified 42 genes exhibiting
AS defects in DM1. Briefly, the methodology of the study was as follows: muscle tissue
(patients: four biceps, two quadriceps, one tibialis anterior, one diaphragm; controls: eight
vastus lateralis) were sampled post-mortem from eight DM1 affected individuals and eight
unaffected controls. Selection of the postmortem DM1 samples were based on high integrity
of RNA present in the sample and presence of splicing misregulation of INSR and AP2A1,
and then compared to quadriceps biopsy samples from eight unaffected controls.
mRNA was extracted from the samples, purified and hybridized to GeneChip™ Human
Exon 1.0 ST microarrays. Putative AS defects were identified using a mixture of existing meth-
ods, such as Affymetrix’s PLIER, DABG and Alternative Transcript Analysis Methods for
Exon Arrays, and new methods proposed and described by the authors. Identified putative
defects were validated using RT-PCR in 50 DM1 subjects, yielding 42 genes with confirmed
AS defects.
Nakamori et al. report several technical obstacles with this approach, with the initial version
of their pipeline suffering from as many as 80% putative AS defects failing to replicate with
Reverse Transcription-PCR. Further analysis suggested that this occurred when signal inten-
sity for the entire transcript or a particular exon was low, overall expression of a transcript was
strongly up- or down- regulated in DM1 relative to normal controls, or signal intensity of an
exon was inappropriately high relative to other exons in the same transcript [8].
Batra et al. [9] re-used the dataset of Nakamori et al. [8] and used similar techniques to filter
down the data, in a search for genes with dysregulated APA. Their selection criteria focused on
probesets with over 2-fold change in DM1 or DM2 vs. unaffected controls, excluding genes
that were represented by� 5 probesets, retrogenes and non-protein coding genes, which
resulted in pre-selection of 438 probesets. The authors performed visual inspection of all pre-
selected probesets identifying 123 APA events belonging to 80 genes.
Evaluating potential biomarkers of DM1
It is well established that the primary determinant of both age at onset and many progressive
DM1 symptoms is the CTG repeat length [18–20]. Separate efforts have shown that case/con-
trol status in DM1 results in detectable AS changes in the mRNA profile of skeletal muscle
(Nakamori et al. 2013; Batra et al. 2014). Our work acts as a bridge unifying both lines of inves-
tigation. In this research, rather than regarding DM1 status as a binary variable, we view DM1
as a spectrum of disease, the severity of which is quantified by the length of the DM1 CTG
repeat in any individual patient. Based on the knowledge of the causative effect of CTG expan-
sion on downstream pathology, and the important role of AS defects in this pathology, we
thought it should be possible to capture the effect, which the length of the CTG repeat has on
mRNA expression in muscle into a simple statistical model, based on partial least squares
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regression (PLSR). Using the model we can predict the size of the DM1 CTG repeat from the
mRNA profile significantly better than a random predictor. We propose that the model can
serve as a valuable tool in evaluating efficacy of any treatment for DM1 as such treatment
enters pre-clinical or clinical trials, by enabling investigators to directly quantify the treatment
effect as measured by effective reduction of DM1 CTG repeat length rather than simply assess-
ing the shift in AS of any one transcript. As disease severity is directly tied to CTG length,
using this approach has the potential to yield more clinically meaningful interpretations of AS
changes. For instance, an AS event that is dramatically shifted to the opposite extreme by even
a small increase in the number of CTG repeats will yield a large signal on a case-control basis,
but may not be closely tied to disease severity within the DM1 population and thus may not
make a good reporter of an intervention as it may require a unrealistically large effect size to
revert it to the non-disease associated range. However, as such an AS event yields little dis-
criminatory power with regard to CTG repeat within the DM1 population, it would not be
selected as a major contributor to our predictive model. Thus, our model has the potential to
enrich for AS events that have more direct clinical relevance rather than absolute changes.
We would like to stress here that “effective reduction” in the case of most candidate treat-
ments will not be an actual reduction in the repeat length (with notable exception of candidate
treatments based on gene editing). Rather, an “effective reduction” is a reduction of “effective
repeat length”, i.e. repeat length as judged by the degree of splicing changes. This can be dem-
onstrated with an example of a patient with a certain pre-treatment repeat length, and both
physiological and molecular symptoms characteristic for that repeat length. If such patient
were to undergo an effective treatment, we would expect these symptoms to be partially
reversed, and our predictive framework to predict a shorter repeat length than the patient’s
actual repeat length. Subject to the correctness of our understanding of the molecular patho-
physiology of the splicing changes, which we rely on to predict the effective repeat length, we
expect that the reversal of the splicing changes would occur immediately after the release of
inactivated AS and APA factors, such as MBNL1. This release should in turn happen immedi-
ately after a candidate therapeutic were to reach a clinically significant level in the relevant tis-
sue. We expect this to happen on a timescale of days to weeks, unlike the reversal of
physiological symptoms, which we would expect to happen on longer timescales.
Materials and methods
The dataset
As part of the Dystrophia Myotonica Biomarker Discovery Initiative (DMBDI) microarray
analysis was used to investigate mRNA profiles in quadriceps muscle from 36 participants,
including 32 DM1 cases and four unaffected controls. One DM1 patient refused blood dona-
tion, thus genetic analyses were only performed on 35 participants. All DM1 cases genotyped
were heterozygous for the expanded CTG repeat and the mode of the length of the DM1 CTG
expansion (Modal Allele Length, MAL) was determined by small-pool PCR of blood DNA for
35/36 patients [21]. For this work we did not attempt to measure the repeat length from mus-
cle, due to a very high degree of repeat instability in muscle cells [3] and associated difficulties
in its experimental measurement. One patient refused blood donation. For each of the 35
blood-donating patients mRNA expression profiling of blood was performed using the Affy-
metrix GeneChip™ Human Exon 1.0 ST microarray. For 28 of 36 patients a successful quadri-
ceps muscle biopsy was obtained. The muscle tissue was mRNA profiled using the same type
of microarray. In total, a complete set of samples (blood and muscle) was obtained for 27 of 36
patients. mRNA profiling was carried out by the GeneLogic service lab (on a fee-for-service
basis) using standard Affymetrix hybridisation protocol.
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Principal Component Analysis (PCA) was performed on both blood and muscle profiles,
and visual inspection was carried out to detect the presence of outliers. Zero outliers in the
blood batch and four outliers in the muscle batch were identified and expression profiling was
repeated for these patients. For the analysis we used only the repeated profiles.
The study was approved by the ethics committee of the Faculty of Medicine at LMU Munich,
Germany; University of Rochester Research Subjects Review Board, Rochester, New York and
University of Florida Institutional Review Board, Gainesville, Florida, USA.
It should be noted that our dataset differs from the dataset collected by Nakamori et al. in
the following ways:
1. We did not perform confirmatory RT-PCR analyses.
2. Our dataset includes both blood and muscle tissue samples.
3. The number of mRNA-profiled participants is about twice the size of the discovery dataset
of Nakamori et al., however, we did not perform a follow-up validation study.
4. Unlike Nakamori et al. we have additional information to participant’s case-control status,
specifically, the mode of the CTG repeat length from blood (MAL). We also estimate the
repeat length at birth (Progenitor Allele Length, PAL) using a previously developed method
[18].
5. We sample from the same muscle group (quadriceps), as opposed to from a wide range of
muscle groups (biceps, quadriceps, tibialis anterior, diaphragm, vastus lateralis) for all
study participants, which eliminates a potentially important confounding effects.
6. All our participants were alive at the time of sample collection, which eliminates another
potential confounder, but other potential confounders still remain, see Limitations.
The dataset is deposited to Array Express with accession number E-MTAB-7983.
Affymetrix GeneChip™ human exon 1.0 ST microarray
The microarray chip used was the Affymetrix GeneChip™ Human Exon 1.0 ST microarray,
which contains over 5 million probes, i.e. short cDNA sequences, which target transcribed
regions with high specificity. Each probe in the HuEx chip contains precisely 25 nucleotides.
Consequently, transcribed regions of interest, which are shorter than 25 nucleotides, for exam-
ple some of the short exons, are not targeted. This is an important limitation in the context of
DM1, as some AS events previously described in DM1, such as AS of exon 5 in cardiac tropo-
nin T (TNNT2) [22] cannot be detected.
Each continuous section of DNA can be targeted by a collection of up to four probes,
referred to as probeset. DNA sections targeted by the chip include known and suspected coding
exons in known and suspected genes, as well as non-coding genomic features, including 5’ and
3’ UTRs, and various other types of transcribed or hypothetically transcribed DNA (miRNA,
rRNA, pseudo-genes, etc.). All probes targeting such a region belong to a single probeset. Pro-
besets are further grouped into transcription clusters, which correspond to the entire genes.
Data preparation and analysis
We designed and built a pipeline, programmed in Python, which has the following data prepa-
ration capabilities: Reading raw Affymetrix CEL v4 files (peer reviewed and merged into Bio-
python [23, 24]); quantile normalisation and log2 transformation of intensity data; strict
annotation of Affymetrix probes using GENECODE v26 lift 37 through selecting probes corre-
sponding to annotated GENECODE transcripts of type “protein_coding”, annotated genes of
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type “protein_coding” and exons of type “CDS” or “UTR”. Appendix S1 Appendix. gives full
source code, user manual and additional explanation of each step of this pipeline.
The pipeline’s final output are two directories: “experiment_muscle” and “experiment_-
blood”, each containing 19,826 files, with each file corresponding to a single gene (e.g. TNNI1)
whose filenames correspond to HGNC gene names. The following is a two-line excerpt from
one of such files, “experiment_blood/TNNI1”. Data for several patients has been removed to
enhance clarity:
In each file, the first row is a header containing tab-separated names of data or metadata
types contained in a given column. Below we give a brief description of some of the data or
metadata types:
• seq5to3—unlike Affymetrix we always report the sequence in 5’ to 3’ direction, and always
with regards to the plus strand, even if the coding sequence is contained on the minus strand.
• genecode_left, genecode_right—these are genomic coordinates as reported by a reference
assembly (GRCh37). Following convention, first coordinate is 1-based, and coordinates are
left-, right- inclusive.
• x, y give the x and the y coordinates of probes on the chip.
• patient_�—these are quantile normalised and log2-transformed intensities at the given
probe for the given study participant.
Each subsequent row contains data and metadata for a single probe.
We develop a predictive model, which closely follows that of Lee et al. [17].
At a conceptual level, the model takes probe intensities (records under the patient_� head-
ers) as the model’s input. It then predicts the CTG length as the model’s output. Throughout
the manuscript we often refer to the model’s predictions as “predicted MAL” or “effective
repeat length”. The effective repeat length is a single numeric value, which allows us to capture
the extent of alternative splicing defects using a familiar concept, i.e. the length of the disease-
causing CTG expansion.
The model works with pre-selected sets of genes that act as candidate biomarkers. For this
purpose, we look at the following collections of genes:
1. A previously identified selection of genes, listed in S2 Appendix and identified by Nakamori
et al. [8] as genes whose AS is disrupted in DM1. We codename these genes “DM1-AS”.
gene_name probeset_id seq5to3plus chrom strand
,! genecode_left genecode_right x y
,! patient_111747589 patient 117440822 . . .
,! patient_896445336
TNNI1 2450836 TGGCCTGTGCCTCGCCGTAGACTGC chr1—
,! 201390827 201390851 195 793
,! 6.69115092487 6.44442470429 . . . 6.86989190909
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2. A previously identified selection of genes, listed in S3 Appendix and identified by Batra
et al. [9] as genes whose AP is disrupted in DM1. We codename these genes
“DM1-APA”. The overlap of this list of genes with DM1-AS is a list of two genes: LDB3,
MBNL2.
3. A single gene (which also belongs to DM1-APA), Troponin I1, slow skeletal type, TNNI1.
We codename this single-gene collection “TNNI1”. The gene was chosen post-hoc.
4. All human genes, as identified in data preparation step. We codename this collection “ALL”.
Then we execute eight separate statistical analyses (four muscle and four blood analyses),
based on these groups of genes. Each analysis was carried out as follows:
1. We randomly split our data into two sets, the training and the testing set, each containing
70% and 30% of participants respectively. We restricted our analysis only to genes, which
belonged to a particular group of genes being studied (DM1-APA, DM1-AS, TNNI1,
ALL)
2. Following Lee et al., we select (up to) 500 probes whose intensities across all patients in the
training set are most correlated with their corresponding MAL. We work at the level of
individual probes, which allows us to circumvent issues around GC-correction and probe-
set aggregation. Probe data are fed directly into the model.
3. Again using the training set, we trained a 2-dimensional Partial Least Squares Regression
(PLSR) model on selected probes as features and corresponding MAL as the model output,
which we later used to predict MAL in the testing set, again following Lee et al..
4. We repeated steps 1 to 3 10,000 times.
5. We report coefficient of determination (R2) of the predicted MAL with the measured MAL
across all folds obtained in step 4. Given that both the predicted MAL and the measured
MAL are single numeric values, the computation of R2 does not suffer from issues relating
to a high number of predictors.
6. We simulated a distribution of R2 of a random predictor, and obtained a p-value for the
prediction of R2 in step 5.
To confirm that any observed signal is not a by-product or an artifact of the mathematical
model used, or its implementation, we carried out the same kind of analysis using three other
mathematical models:
1. lasso
2. random forest regression
3. linear regression
To relate our findings to a potential clinical setting, we present power analysis relating vari-
ous potential treatment effect sizes to their detectability in future clinical trials. The power
analysis was performed as follows:
1. We simulated the distribution of MAL prediction error for the best predictor. This was
achieved in a similar way to the computation of the coefficient of determination: we
used the same method of splitting our data into a training and a testing set, selecting
features, training the model and making predictions. The only difference was that
instead of computing R2, we used the predicted MAL set to compute the prediction
error.
PLOS ONE Towards development of a statistical framework to evaluate myotonic dystrophy type 1 mRNA biomarkers
PLOS ONE | https://doi.org/10.1371/journal.pone.0231000 April 14, 2020 7 / 19
2. We simulated the distribution of predicted MAL post-treatment, with the assumption that
predicted MAL would be reduced by 10%, 20% or 50%, which correspond to, respectively,
small, medium and large treatment effect size.
3. We established the rejection region for a null hypothesis of “no treatment effect” at α = 0.05.
4. We simulated the power, (1—β), for studies involving 10 to 200 participants, in increments
of 10 participants.
Results & discussion
Performance of PLSR-based MAL predictors in muscle and blood
Using our predictive model based on PLSR and a selection of candidate biomarkers: DM1-AS;
DM1-APA; TNNI1 and ALL, we can report the following capabilities to predict MAL from
mRNA profiles.
In muscle we can detect strong signal for some of the selected candidate biomarker sets,
with the two strongest predictors, DM1-AS and TNNI1, giving us R2 and p-values equal to
0.285, 0.322 and 0.0046, 0.0023 respectively. All values of R2 and p-values, as well as Root
Mean Square Deviation (RMSD) are given in Table 1. In particular, DM1-AS looks promising
as a set of biomarkers, giving weight to the findings of Nakamori et al. [8].
Based purely on numerical analysis of obtained results, one could declare TNNI1 as the best
predictor of MAL in muscle, but care must be taken, as we chose this particular gene post-hoc
and its true predictive value might have been influenced by issues related to multiple hypothe-
ses testing. An additional validation study would have to be performed before drawing any
conclusions on the performance of TNNI1 as a DM1 biomarker.
A safer belief can be assigned to the predictive value of “DM1-AS” and “DM1-APA” as both
sets of genes have been previously implicated in DM1 [9], and we can detect strong signal
from both sets of genes, with models based on these genes capturing respectively 28.5% and
15.1% of MAL variance in our study group.
One has to note an interesting observation relating to the “curse of dimensionality” and the
performance of our PLSR-based model. Although TNNI1 is a subset of DM1-APA, TNNI1 on
its own is a much better predictor than DM1-APA, as increasing the number of genes (fea-
tures) increases the dimensionality of our data and worsens the prediction delivered by the
PLSR model.
A single run of 10,000 repetitions of a simulation can be visualised by plotting the predicted
value of MAL against the actual, adding a small amount of random noise on the x-axis. For
DM1-AS in muscle, such visualisation is given in Fig 1.
In blood we cannot detect significant signal for most candidate biomarkers, with R2 not sig-
nificantly respectively greater and lower than would be expected by chance, except in one case,
DM1-APA, whose R2 and p-value are 0.15 and 0.0564 respectively. Full R2 and (uncorrected)
p-values are given in Table 2. Poor performance of blood data acting as a predictor of repeat
length is perhaps not unexpected, as all candidate biomarkers evaluated in this study are based
Table 1. 10000 repetitions of a simulation predicting MAL from muscle cross-validated with a testing set separate from the training set.
DM1-AS DM1-APA TNNI1 ALL
R2 0.285 0.151 0.322 0.085
p-value 0.0046 0.0455 0.0023 0.1396
RMSD 327.821 361.443 326.266 370.429
https://doi.org/10.1371/journal.pone.0231000.t001
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on prior analyses of muscle data, and might not be expressed, or only lowly expressed in blood,
or that expression profiles might be very different from expression profiles in muscle. Only
DM1-APA can potentially carry some predictive value, however, not as strongly as in muscle.
Other models
As described in Data preparation and analysis, we have used a model based on feature selection
from sets of candidate mRNA biomarkers to predict the MAL of DM1 CTG repeat using
PLSR. As reported in Performance of PLSR-based MAL predictors in muscle and blood, the
set of genes DM1-AS is the strongest predictor if we limit our consideration to predictors cho-
sen a-priori (i.e. excluding TNNI1).
A potential source of criticism could be that the effect observed is a technical effect due to
the choice or the implementation of the mathematical model used (PLSR). We thus re-ran the
analysis as described before in Data preparation and analysis using three mathematically dis-
tinct models: lasso, random forest regression and linear regression.
Fig 1. DM1-AS muscle MAL prediction. 10,000 repetitions of cross-validated MAL prediction from genes labeled
DM1-AS from muscle for 18 training samples.
https://doi.org/10.1371/journal.pone.0231000.g001
Table 2. 10000 repetitions of a simulation predicting MAL from blood cross-validated with a testing set separate from the training set.
DM1-AS DM1-APA TNNI1 ALL
R2 0.044 0.104 0.049 0.011
p-value 0.2239 0.0586 0.2014 0.5506
RMSD 363.334 344.767 392.414 371.649
https://doi.org/10.1371/journal.pone.0231000.t002
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We report the performance of these models in Table 3:
It should be noted that all models pick up statistically significant signal with both PLSR,
lasso and linear regression performing almost equally well, and random forest performing
about two times poorer (but still significantly better than a random predictor), which allows
us to conclude that the effect observed is unlikely to be a modeling artifact.
Qualitative characterisation of the strength of observed correlations
The strength of observed correlations of CTG repeat length and effective CTG length as mea-
sured by AS defects needs to be put in the context of similar correlations observed in other
studies. We should distinguish here studies looking at large cohorts with a wide variety of clini-
cal symptoms, e.g. studies including both congenital and late-onset participants, from studies
looking at a relatively narrow range of participants, e.g. adult-onset, ambulatory participants
only. In the former, highly variable cohorts, CTG repeat length has been shown to explain a
large fraction of the variance of such DM1 symptoms as age-at-onset (e.g., R2=0.640 in Mora-
les et al. [18]). It has been much less successful in the latter type of studies, where study selec-
tion criteria indirectly limit the range of observed CTG repeats.
The study described here is of the latter type, with selection criteria being adult-onset,
ambulatory DM1 patients. In this context, and taking into account the modest size of this
study, the most significant correlation, i.e. between effective CTG length as predicted from
DM1-APA and the true CTG length as measured using PCR (R2=0.29) actually compares
favourably with symptoms most strongly correlated in similar studies, such as correlation of
CTG repeat length and grip strength (R2=0.443), pinch strength (R2=0.419) and ankle dorsi-
flexor strength (R2=0.202) [19].
A tempting question to ask is whether the study presented here allows us to draw conclu-
sions with regards to explainability of AS defects with CTG length. Unfortunately, the study
design did not include any biological or technical replicates. As a result, we were unable to
quantify the relative contributions of different factors to overall variance in predicted CTG
length. An extended discussion of this theme is present in section Limitations.
Applying the model in a clinical setting
Let us now consider the potential application of this predictive model in the context of evaluat-
ing efficacy of a DM1 treatment. DM1 patients would undergo muscle biopsy before starting
the treatment, and another biopsy after the treatment had been started and necessary biologi-
cal changes to reverse DM1 symptoms had occurred. Both biopsies would be mRNA profiled,
and the resulting profiles would be used to perform MAL predictions. We expect that pre-
treatment prediction would correspond to the actual MAL of any given participant. We expect
that post-treatment prediction of MAL would correspond to an “effective MAL”, which we
would expect to be lower than the “actual MAL” in affected participants, as long as the treat-
ment is effective and DM1-induced disruption of AS or APA, as measured by DM1-AS or
DM1-APA biomarkers is measurably reversed in obtained mRNA profiles. Pre-treatment and
post-treatment predictions could be combined into a statistic that, given enough patients,
Table 3. 10000 repetitions of a simulation predicting MAL from muscle, using DM1-AS as a predicting set and a selection of mathematical models.
linear regression PLSR lasso random forest
R2 0.291 0.285 0.286 0.149
p-value 0.00418 0.00457 0.00454 0.0478
https://doi.org/10.1371/journal.pone.0231000.t003
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would allow us to quantify the efficacy of the treatment at the molecular level. We discuss this
idea further in the chapter Power Analysis.
In some respects, such a study could allow for better performance of the model, conceptu-
ally, it should be easier to capture DM1 specific expression changes in a setting where noise
due to varied genetic backgrounds of participants can be reduced by looking at pairs of mea-
surements of a single participant. There are a number of details in such study design, which
need to be discussed by the community and decided upon, among others:
1. The mathematical basis of the model used. We propose a PLSR-based model, and demon-
strate that models based on lasso and linear regression perform similarly, but other models
can also be considered, in particular the work of Azencott et al. [16] in the context of L1-
penalised regression (lasso) looks promising as it allows to incorporate prior biological
knowledge, in the form of protein-protein interaction networks or other types of graph
ontology, into the model, through the introduction of additional penalties based on discrete
Laplacian, or apply alternative modelling strategies based on network flow, thereby increas-
ing its predictive power.
2. The training/testing pre-treatment/post-treatment data split and which genes should be
included in the model input.
3. The size of the study. Predictions in our study are based on 24 participants for blood and 18
for muscle. How much would the models’ predictive power improve with a larger dataset?
4. Establishing the clinically relevant effect size. Pandey et al. [7] report various efficacies of a
candidate DM1 treatment ISIS 486718 to lower toxic DMPK concentrations in wild-type
and transgenic animal models and a range of tissues, starting with the efficacy of about 50%
in cardiac muscle, through about 70% in skeletal muscle, up to about 90% in liver and skele-
tal muscle. However, measuring DMPK levels may not necessarily directly correspond to
the efficacy of treatment to reverse symptoms, as the relationship between the quantity of
the toxic transcript, splicing disruption and eventual clinical symptoms may be complex
and non-linear. Conservatively, we need to expect the rate of symptom reduction to be
lower than the reported 50% to 90%. A difficult open question is what minimum treatment
efficacy we are willing to accept as clinically significant?
We would also like to note that the statistical framework proposed here is not limited to the
experimental technique used. The framework could equally well be applied to new data sets,
including RNA-seq, as long as they feature a sized CTG repeat for each participant in the
dataset.
An informal setting to explore the dataset
As this work is the first presentation of the DMBDI dataset, we recognise that further work
might build on the dataset in ways which differ from our approach and cannot be predicted at
the current stage of our understanding of DM1-related AS/APA changes. To facilitate this, we
would like to propose a tool which on one hand allows for informal, interactive and explor-
atory analysis of the dataset and on the other allows the flexibility of building a custom analysis
—just like the one presented here.
The tool is available online [25], and is implemented as a jupyter notebook with custom
visualisation of filtered and normalised DMBDI data. The flexibility of the tool comes at a cost.
In order to support arbitrary bioinformatics analyses, we have to support arbitrary code execu-
tion, which in turn requires protecting the tool with a password. We will share the password
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with any bona fide researcher upon request. A walk-through video showcasing the capabilities
of the tool is available on youtube [26].
The major capability of the tool is the ability to produce “railway plots”. Railway plots intro-
duce the idea of a Manhattan plot from genomics community into transcriptomics. Each point
represents statistical significance of the change of expression signal at a single probe across
DM1 spectrum, as supported by experimental data. Points which belong to the same probeset,
are identically coloured. See Fig 2 for an example railway plot.
In a railway plot the y-axis represents negative logs of p-values of a two-tailed test against a
null hypothesis of no expression change at a single probe across the DM1 spectrum. Fig 3 visu-
alises one of such linear regressions for a probe belonging to probeset 245089. The logs of p-
Fig 2. TNNI1 railway plot shows an APA event at probeset 245089.
https://doi.org/10.1371/journal.pone.0231000.g002
Fig 3. Linear regression of expression intensity at a single probe belonging to probeset 245089 against DM1 repeat
length.
https://doi.org/10.1371/journal.pone.0231000.g003
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values are signed in accordance with the direction of the slope of the regression, with negative
values indicating splice-out and positive values indicating a splice-in type of event.
For each splice-out and splice-in directions in the plot, we show thresholds of statistical sig-
nificance. The first pair of thresholds (faded red and blue respectively) correspond to statistical
significance threshold of 0.05. The second pair of thresholds correspond to 0.05/n, where n is
the total number of probes in the plot (saturated red and blue respectively). This is analogous
to the way Manhattan plots are often presented for GWAS.
Turning our attention from statistics to biology, we can ask about a likely biological inter-
pretation of an observed splice-out event detected at probeset 2450829. Using Ensembl [27],
see Fig 4), we can identify transcript TNNI1-203, which is the only GENECODE transcript fea-
turing a probe selection region targeted by the probeset 2450829, in form of an alternative 3’
UTR. This allows us to suggest that TNNI1-203 is downregulated in participants with longer
DM1 repeats. GENECODE annotation further informs us that TNNI1-203 is an APPRIS P2
transcript (i.e. a candidate principal variant, a designation which comes from high level of sup-
port for functionality of the isoform), and is not a CDS incomplete transcript, which allows us
to strengthen our belief in the fact that this is a biologically functional/ protein-coding tran-
script, which can play a role in the DM1-related AS/APA changes.
Finally, and returning back to statistics, we can ask whether high significance of the splice-
out event is a result of multiplicity effect, given that the gene was chosen post-hoc from a pool
of candidate biomarker genes as determined by Batra et al. and Nakamori et al. [8, 9]. A stan-
dard approach here would be to combine the data from the discovery dataset with the data
from the replication dataset, compute a more powerful test, and apply multiplicity correction.
This is not possible in this case as the discovery dataset, underlying both studies is a case-con-
trol dataset, whereas our dataset captures DM1 status as a continuous variable via DM1 CTG
Fig 4. Visualisation of genomic coordinates of TNNI1 transcripts using Ensembl.
https://doi.org/10.1371/journal.pone.0231000.g004
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repeat length measurement. An alternative is to combine both p-values using, e.g. Fisher’s
method [28], which shows that the combined p-value against the null hypothesis of no change
of signal intensity at the probeset 2450829 is 4.19 × 10−10. Computing the Bonferroni correc-
tion with multiplicity factor of 1.4 million, equal to the total number of HuEx probesets [29],
shows that the combined p-value based on the discovery dataset and our dataset is 5.88 × 10−4.
This is a strong confirmation of the significant correlation of DM1 status with TNNI1-203
downregulation. Details of the computation are available in S1 Appendix.
Power analysis
Our final contribution, which is of critical significance in the context of any future clinical trial
is a power analysis of the current model. We report power for a selection of possible treatment
effect sizes (10%, 20% and 50% reduction in effective MAL on a per-patient basis) and a selec-
tion of study participants. Our power is defined as (1 − β), where β is a supremum of the prob-
ability of committing a type II error, with the supremum of the probability of committing type
I error (α) kept at a constant 0.05. Table 4 reports power, (1 − β), to detect treatment effect of a
two-tailed test with p-value cut-off of 0.05 (0.025 per tail), with the statistic simulated from
MAL predictions of our model, for varying treatment effect and study sizes. We try to keep
our cohort sizes realistic for a rare disease, i.e. we allow for patient numbers to range from 10
to 200.
Ideally we would like to be able to achieve power of more than 95%, even with small treat-
ment effect sizes and a small number of patients, but our model, trained on 18 participants,
doesn’t allow for such level of control over type II error for all but medium or large treatment
effects (more than 20% and 50% respectively) and large (more than 140 participants) or
medium-sized (more than 30 participants) clinical trials respectively.
Table 4. Power analysis. Entries in the table report power to detect treatment effect based on the size of a cohort (from 10–200 participants) and the treatment effect of the
study to reverse splicing changes (10, 20 and 50%). Entries denoting power greater than 95% are presented in boldface.
study size (participants) treatment effect 10% treatment effect 20% treatment effect 50%
10 0.100 0.209 0.635
20 0.131 0.322 0.855
30 0.162 0.423 0.947
40 0.193 0.517 0.981
50 0.226 0.596 0.994
60 0.259 0.671 0.998
70 0.283 0.723 0.999
80 0.311 0.772 0.9998
90 0.339 0.816 0.99998
100 0.370 0.851 0.99998
110 0.396 0.881 0.99999
120 0.418 0.901 1.0
130 0.448 0.924 1.0
140 0.467 0.937 1.0
150 0.500 0.952 1.0
160 0.523 0.962 1.0
170 0.545 0.969 1.0
180 0.568 0.977 1.0
190 0.589 0.981 1.0
200 0.613 0.986 1.0
https://doi.org/10.1371/journal.pone.0231000.t004
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However, our results combined with expected improvements of the model performance
due to larger training samples, and better gene selections, such levels might be reached for
medium treatment effect size (20% reduction in effective MAL) and large clinical sizes.
Limitations
Tissue sampling. A source of potential criticism is that muscles of DM1 patients have
physiological differences (atrophy, increased fat content), especially when disease is severe.
Quite possibly observed changes in AS/APA are partly attributable to these physiological dif-
ferences in DM1 as opposed to purely biomolecular differences. The structure of this counter-
argument could be as follows:
Muscles of DM1 patients have higher fat content than affected controls. Muscle samples
collected from DM1 patients have higher ratio of intermuscular adipocytes to myocytes. Adi-
pocytes have different AS/APA profiles than myocytes. Observed AS/APA changes in the
DM1 spectrum are mostly derived from differences in adipocyte/myocyte profile. As a result,
mRNA study of muscle tissue is no more effective (and possibly less effective) than a blinded
study based on pathophysiological inspection of the tissue.
This argument can, of course, be extended to other physiological changes than increased fat
content, and other molecular events than AS/APA. Bachinski et al. [30], for example, propose
that splicing changes could be a secondary result of muscle regeneration.
There are multiple ways to address these concerns:
1. Alternative predictive model design based on tissue culture models, where in vivo limitations
are reduced, with homogeneity of the cellular composition of the model being a big advantage.
2. Investigating methods to correct for potential “physiological” covariates (e.g. fat content),
using purely statistical techniques to estimate covariate influence from gathered data and
existing prior information (e.g. mRNA profiles of adipocytes), or biological methods, such
as a recent effort to collect higher quality muscle samples through MRI-guided biopsy [31].
3. Discovering DM1 biomarkers in blood, as opposed to muscle. Blood, being much more
homogeneous tissue than muscle is expected to be less prone to the existence of con-
founding variables. Additionally, necessity of muscle sampling was highlighted to be a
“main drawback” [8]. However, achieving this would require at least two separate, suc-
cessful studies, one to identify biomarkers and one to evaluate them. Even if blood bio-
markers were identified, their clinical utility might be limited, as a reduction of an
effective MAL in blood would not be as direct evidence of treatment effectiveness as such
reduction in muscle.
4. Introduction of positive controls in experimental designs. Biological samples in the positive
control group would be composed of tissue collected from individuals with other muscular
dystrophies (e.g. Becker muscular dystrophy, Duchenne muscular dystrophy, facioscapulo-
humeral muscular dystrophy or tibial muscular dystrophy). These diseases feature dystro-
phy and increased muscle regeneration program as part of their phenotype, but without
disruption of RNA-binding splicing factors. Absence of DM1-specific splicing changes in
these positive controls would allow to rule out alternative explanations of mis-splicing
mechanisms (e.g. muscle regeneration) and strengthen our belief in currently accepted
models of molecular pathomechanism of DM1.
5. Confining the analysis to transcripts which are exclusively or predominantly expressed in
skeletal muscle, not fat.
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Weak correlations of predicted and true CTG length. Correlations described in the
study are quite modest, with effective CTG length as predicted from DM1-APA and the true
CTG length as measured using PCR giving us the highest correlation with r2 = 0.29. We
would like to group potential reasons for this into two categories of factors, which capture
the most likely reasons for weak correlations: 1. Weak correlation of CTG repeat length with
progressive DM1 symptoms in general (potentially including the extent of AS defects). This
highlights a shortcoming of our current understanding of molecular pathology of DM1. 2.
Study design, and in particular experimental techniques used in the study introducing large
amounts of technical noise. While the first factor is well known [3], and a deeper under-
standing of DM1 pathomechanism, e.g. through further study of the RNA binding proteins
(RBPs) is warranted, the study design (including experimental factors) is likely to be a major
contributing factor. Unfortunately, the study design did not include any biological or techni-
cal replicates, so we were unable to quantify the relative contributions of different factors to
the error terms present in both measurements, and especially the measurements of AS
defects. Consequently, we are limited to a primarily qualitative discussion of the study
limitations:
1. We are studying a complex, noisy system: atrophied muscle of individuals who volunteered
in the study. These individuals exhibited difference in age (which would contribute to
somatic mosaicism discrepancy between blood/muscle), sex, and would have different life-
styles. All these factors can contribute to DM1 pathomechanism in a way, which couldn’t
be captured with CTG repeat sizing in blood.
2. The platform we are using (Human Exon array) cannot detect all available signal (e.g. some
of the short exons are not targeted). There are several other issues with the experimental
setup: measurements are based on just 9 pixels from the original image from the scanner.
Most probes have no technical replicates. The array used was not a junction array, it’s diffi-
cult to attribute within-transcript change to any particular AS events/defects. Probe GC
content can be a confounder (but the method we’ve used is resistant to any additive bias
from GC content). Dyes used in microarrays are very sensitive to daily conditions in the
laboratory, e.g. it has been shown that levels of atmospheric ozone has significant effect on
the measurements [32]
3. Small sample size. In the study we obtained a complete tissue collection from only 27 indi-
viduals. Intuitively, this is a small sample size when judged by a typical size of a phase 1 clin-
ical trial. Simulation confirms the intuition that a better model could be obtained by simply
training on a larger dataset. Specifically, R2 of 28.5% was reported for a model which used
18/9 as the training/testing split for the 27 individuals. Using the same model with 14/13 as
a splitting strategy, performance of the model measured R2 to be only 17.6%. We would
like to note that our estimate is conservative, and a larger sample size would likely give us a
higher predictive strength.
4. The original list of biomarkers was discovered in different muscle groups.
5. Our model is quite simple—it doesn’t encode biological intuition behind alternative splic-
ing or alternative polyadenylation. All features are treated as independent, even within a
single transcript.
6. The repeat was sized in blood as opposed to muscle. Repeat sizing in muscle is very chal-
lenging, but would likely give stronger levels of signal.
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Conclusion
In this study we design and build a model based on PLSR, which can explain as much as 28.5%
of the variance in DM1 CTG trinucleotide expansion from mRNA splicing data. Such explain-
ability is only obtained when the model is trained on expression data from genes previously
identified by Nakamori et al. [8] as having disrupted AS on data obtained from muscle sam-
ples. We show how such model could be used in a clinical setting in the context of emerging
DM1 treatments, and report power analysis to detect treatment effect depending on size of the
treatment effect, type 1 error (α) and potential size of the clinical trial.
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